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In view of the mortality associated with Pseudomonas
aeruginosa (PSA) ventilator-associated pneumonia
(VAP) and the frequency of inadequate initial empiric
therapy, recent findings underscore the need for a
different management paradigm with effective
anti-pseudomonal vaccines for prophylaxis of patients
at risk. The association of virulence factors is a variable
that splits PSA in two phenotypes, with the possibility of
adjunctive immunomodulatory therapy for management
of virulent strains. We comment on recent advances in
and the state of the art of PSA-VAP management and
discuss a new paradigm for tailored and optimal
management.ventilator-associated pneumonia (VAP) was present, mostIn the previous issue of Critical Care, Lu and colleagues
[1] reported a visionary study assessing the distribution
of Pseudomonas aeruginosa (PSA) serotypes in patients
with ICU pneumonia and suggested differences in out-
comes depending on serotypes. In this report, serotype
O6 predominated, being associated with better clinical
outcomes than serotype 011, which were frequently pro-
ducing toxins secreted by the type III secretion system
(TTSS). These findings have important implications for
both clinical practice and future studies.
In an international study of over 1,200 ICUs in 75
countries, the risk of infections, including those due to
Pseudomonas species, was found to increase with duration
of ICU stay; in addition, infection was associated with an
increased risk of mortality [2]. In 2014, at a time when
multidrug-resistant clones are emerging and represent
a strong risk of dissemination, we have much more* Correspondence: jrello@crips.es
1Critical Care Department, Hospital Vall d’Hebron, Passeig de la Vall d’Hebron,
119-129, 08035 Barcelona, Spain
2CIBERES, Recinto Hospital Joan March, Carretera Soller Km 1207110,
Mallorca, Bunyola, Illes Balears, Spain
Full list of author information is available at the end of the article
© Rello et al.; licensee BioMed Central Lt
months following its publication. After this tim
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
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We know that one effective agent is equivalent to
two [3,4] but that initial combination followed by de-
escalation improves survival by reducing the risk of
delay in appropriate therapy. We know that resolution
of episodes with appropriate therapy is similar to core
pathogens [5] but that wrong initial therapy is associated
with a resolution similar to that of methicillin-resistant
Staphylococcus aureus [6].
Pulsed-field electrophoresis analysis performed in an
ICU with a high prevalence of PSA identified the geno-
types of more than 1,700 isolates [7]. Interestingly, the
most frequently isolated clones were responsible for gut or
skin colonization, in addition to respiratory colonization,
but were only rarely associated with pneumonia. When
patients achieved clinical resolution without major conse-
quences. On the other hand, non-related clones suggestive
of prior colonization were associated with a very high
mortality rate [7]. Most clonally related isolates caused
gastric colonization before skin or respiratory tract
colonization, suggesting an association with the tap
water used in the administration of medication. These
findings emphasize that different risk factors may be
implicated depending on whether the clone is due to
exogenous contamination or or as endogenous colonization
from being a carrier. Therefore, conventional identifica-
tion provided by the microbiology laboratory results
is insufficient for assessing the patient and effective
management.
Indeed, recent advances have demonstrated the im-
portance of virulence factors in PSA infections. Al-
though several different mechanisms such as quorum
sensing and biofilm formation have been reported [8],
the TTSS, encoded by PSA, has become one of the most
important and widely studied virulence factors. After
the microorganism has come into contact with the cell,
the needle-like TTSS mechanism allows the bacteria to
inject toxins directly into the cytoplasm of the host celld. The licensee has exclusive rights to distribute this article, in any medium, for 6
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system [10]. Recent studies suggest that failure to eradi-
cate PSA in patients with VAP may be linked to TTSS.
Patients infected with Pseudomonas sp. strains which
express at least one type of TTSS protein (TTSS+) at the
onset of VAP are more likely to have recovered at day 8
post-VAP, whereas eradication is achieved in patients
with undetectable levels of TTSS proteins [11]. The
transfer of our knowledge of the virulence factors to the
clinical setting is crucial in order to evaluate the poten-
tial of virulence factor-directed therapies.
In view of the mortality associated with PSA-VAP
[3,5,12] and the frequency of inadequate initial empiric
therapy [13-15], these findings underscore the need for a
different management paradigm with effective anti-
pseudomonal vaccines for prophylaxis of patients at risk
and the need for rapid diagnostic test methods and
monoclonal-specific antibodies blocking virulence fac-
tors in patients with VAP.
We have also learned that association of virulence factors
is a variable that splits P. aeruginosa in two phenotypes,
with the possibility of adjunctive immunomodulatory
therapy for management of virulent strains [16]. A com-
bination of general risk factors and molecular diagnosis
techniques may identify suitable candidates for inter-
vention. As in invasive pneumococcal infections [17],
further research is required to identify potential associa-
tions of comorbidities and serotypes as well as of sero-
types and specific complications.
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